Asymchem Laboratories (Tianjin) Co., Ltd. Class H (HK:6821)
:6821
Top Page
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
(6821)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$112.00
▲(51.76% Upside)
Action:ReiteratedDate:04/02/26
The score is driven primarily by strong financial flexibility from a low-leverage balance sheet and still-solid profitability, offset by volatile/weaker recent free cash flow. Technically, the trend is strong but overbought signals increase near-term risk. Valuation support is limited due to an unusable P/E input and only a modest dividend yield.
Positive Factors
Low leverage / strong balance sheet
Very low debt and a capital base dominated by equity provide durable financial flexibility. This reduces refinancing risk, supports counter-cyclical investment into capacity or quality systems, and lets management pursue multi-year CDMO contracts without being constrained by leverage.
Negative Factors
Volatile free cash flow
Inconsistent free cash flow undermines the firm’s ability to self-fund capacity expansion, sustain dividends, or pursue strategic M&A. For a capital-intensive CDMO, uneven FCF increases reliance on external financing and can constrain long-term capacity planning and competitive responsiveness.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt and a capital base dominated by equity provide durable financial flexibility. This reduces refinancing risk, supports counter-cyclical investment into capacity or quality systems, and lets management pursue multi-year CDMO contracts without being constrained by leverage.
Read all positive factors
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$48.78B
Dividend Yield1.57%
Average Volume (3M)640.69K
Price to Earnings (P/E)20.0
Beta (1Y)1.44
Revenue Growth12.35%
EPS Growth34.32%
CountryHK
Employees9,595
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.52
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$119.32Price Target Upside61.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.36
Revenue Forecast (FY)HK$9.11B
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical ...
How the Company Makes Money
The company primarily makes money by delivering fee-based contract services to pharmaceutical and biotechnology clients. Key revenue streams typically include: (1) Contract Development (CDMO/CRDMO) fees for process development activities such as s...
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.67B | 5.80B | 7.83B | 10.26B | 4.64B |
| Gross Profit | 2.80B | 2.46B | 4.00B | 4.86B | 2.06B |
| EBITDA | 1.85B | 1.58B | 3.03B | 4.08B | 1.41B |
| Net Income | 1.13B | 948.95M | 2.27B | 3.30B | 1.07B |
Balance Sheet | |||||
| Total Assets | 20.28B | 19.29B | 19.77B | 18.24B | 15.16B |
| Cash, Cash Equivalents and Short-Term Investments | 7.44B | 7.33B | 9.02B | 7.44B | 6.64B |
| Total Debt | 256.47M | 282.53M | 118.71M | 138.35M | 434.49M |
| Total Liabilities | 2.63B | 2.43B | 2.26B | 2.54B | 2.55B |
| Stockholders Equity | 17.64B | 16.85B | 17.48B | 15.65B | 12.61B |
Cash Flow | |||||
| Free Cash Flow | 137.22M | 124.33M | 2.31B | 1.14B | -1.55B |
| Operating Cash Flow | 1.41B | 1.25B | 3.55B | 3.29B | 113.15M |
| Investing Cash Flow | -633.20M | -1.18B | -2.69B | -4.67B | -2.21B |
| Financing Cash Flow | -344.83M | -1.93B | -542.03M | -742.53M | 6.21B |
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Technical Analysis
Positive
73.80
Price Trends
82.32
Positive
80.89
Positive
86.39
Positive
Market Momentum
4.40
Negative
65.73
Neutral
76.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6821, the sentiment is Positive. The current price of 73.8 is below the 20-day moving average (MA) of 83.56, below the 50-day MA of 82.32, and below the 200-day MA of 86.39, indicating a bullish trend. The MACD of 4.40 indicates Negative momentum. The RSI at 65.73 is Neutral, neither overbought nor oversold. The STOCH value of 76.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6821.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$48.78B | 20.04 | 6.54% | 1.57% | 12.35% | 34.32% | |
66 Neutral | HK$43.48B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
63 Neutral | HK$58.22B | 18.63 | 11.48% | 1.04% | 14.50% | -19.24% | |
56 Neutral | HK$27.71B | -6.48 | -12.75% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.31B | -22.62 | -14.53% | ― | 38.56% | 48.26% |
* Healthcare Sector Average
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
96.80
53.85
125.38%
HK:1548
Genscript Biotech
12.81
2.39
22.94%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
21.08
8.88
72.82%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
24.94
10.86
77.13%
HK:2096
Simcere Pharmaceutical Group Limited
13.74
5.76
72.18%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
83.35
54.75
191.43%
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Corporate Events
Asymchem Sets Three-Year Dividend Plan to Balance Shareholder Returns and Growth
Mar 31, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has approved a three-year shareholder dividend return plan for 2026–2028, designed to create a scientific, sustainable, and stable mechanism for profit distribution. The plan seeks to balance reasona...
Asymchem Labs Boosts 2025 Profit and Proposes Higher Dividend
Mar 30, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. reported revenue of RMB6.67 billion for 2025, a 14.91% increase from the prior year, with gross profit rising 16.46% and gross margin edging up to 41.59%. Net profit attributable to shareholders climbed 19...
Asymchem Laboratories (Tianjin) Proposes Final 2025 Cash Dividend
Mar 30, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a Hong Kong-listed pharmaceutical services provider, focuses on contract research and manufacturing to support global drug developers. Its business model centers on offering specialized laboratory and pro...
Asymchem Calls April 2026 EGM to Tweak Share Plan and Governance
Mar 25, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has called its first extraordinary general meeting of 2026 for 17 April in Tianjin, inviting H shareholders of record to attend and vote, with the share register closed from 14 to 17 April. The meeting wil...
Asymchem Calls 2026 H-Share Class Meeting to Approve Share Repurchases and Governance Changes
Mar 25, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has convened its first H Shares Class Meeting of 2026 for 17 April 2026 in Tianjin, following its extraordinary general meeting and A shares class meeting, to seek H-shareholder approval on several governa...
Asymchem Schedules March 2026 Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 16, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has scheduled a board meeting for 30 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider the ...
Asymchem to Repurchase and Cancel 61,000 Restricted A Shares After Staff Resignations
Mar 13, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has approved the repurchase and cancellation of 61,000 restricted A shares previously granted under its 2025 A Share restricted share incentive scheme to five employees who have since resigned. In line wit...
Asymchem Updates Articles to Reflect Capital and Share Structure Changes
Mar 13, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has proposed amendments to its articles of association to reflect recent changes in registered capital and share structure arising from the repurchase and cancellation of part of the restricted A shares un...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.